YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
(RTTNews) - Palisade Bio, Inc. (PALI), a clinical-stage biopharmaceutical company, reported financial results for the second quarter ended June 30, 2026, reflecting a wider net loss and provided a business update. Company Profile Palisade…
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Oppenheimer on Thursday initiated coverage of Palisade Bio Inc., saying the stock offers investors an attractive way to gain exposure to t…
ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America and Europe First patient enrollment anticipated in the second half of 2026; primary efficacy results expected in t…
B Group, Inc. disclosed a new stake in Bright Minds Biosciences(NASDAQ:DRUG) in its May 15, 2026, SEC filing, acquiring 67,500 shares—an estimated $5.43 million trade based on quarterly average pricing. What happened According to a May 15,…
Palisade Bio Inc. (NASDAQ:PALI) is one of the best NASDAQ stocks under $5 to buy right now. On May 12, Palisade reported Q1 2026 earnings, recording a net increase in operating expenses to fund its clinical pipeline. R&D expenses rose to $…
VANCOUVER, BC, April 27, 2026 /CNW/ - Palisades Goldcorp Ltd. (TSXV: PALI) ("Palisades" or the "Company") announces that it has entered into a loan agreement (the "BMO Loan Facility"), as borrower, with Bank of Montreal, as lender ("BMO"),…
We recently compiled a list of the 10 Best Biotech Stocks Under $10 to Buy. Palisade Bio, Inc. is among the best biotech stocks to buy under $10. TheFly reported on April 8 that Wolfe Research initiated coverage of PALI with an Outperform…
On February 17, 2026, B Group, Inc. disclosed a new position in Structure Therapeutics(NASDAQ:GPCR), acquiring 90,000 shares in the fourth quarter. What happened B Group disclosed in a Securities and Exchange Commission (SEC) filing dated…
Key Points B Group acquired 90,000 shares of Structure Therapeutics in the fourth quarter. The quarter-end position value increased by $6.26 million due to the new holding. The new stake accounted for 4.62% of the fund’s 13F assets, placin…
PALI-2108 Abstracts Highlight Gut-Targeted PDE4B Inhibition and Translational Phase 1a Findings in Ulcerative Colitis Carlsbad, CA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinic…
Chaay_Tee / iStock via Getty Images Quick Read: With just two full trading days left in 2025, look for some volatility this week. The S&P 500 is heading for its third consecutive year of double-digit returns, barring a market meltdown this…
We recently published 10 Stocks Lighting Up Market Ahead of Christmas. Palisade Bio Inc. (NASDAQ:PALI) is one of the best performers on Wednesday. Palisade extended its winning streak to a fourth straight day on Wednesday, jumping 5.26 per…
Palisade Bio, Inc. Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease Carlsbad, CA, Dec. 02, 2025 (GLOBE NEWSWIRE) --…
Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease Carlsbad, CA, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.…
Live webcast fireside chat on Thursday, December 4th at 10:30 AM ET Carlsbad, CA, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company advancing next-…
Palisade Bio, Inc. (PALI) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces i…
Seasoned Pharmaceutical leader bringing over 24 years of experience in clinical development across autoimmune, metabolic, cardiovascular, and gastrointestinal indications Company remains focused on advancing PALI-2108 in ulcerative colitis…
First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies Topline safety, PK, and PD data anticipated in Q1 2026 Advances ongoing development of PALI-2108 across fibrost…
PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn’s disease (FSCD) and ulcerative colitis (UC) to address significant unmet medical needs Carlsbad, CA, Oct. 13, 2025 (GLOBE N…
(RTTNews) - Several biotech stocks posted notable after-hours gains on Thursday, October 9, driven by fresh data, strategic updates, and corporate developments. Here's a quick look at the key movers and catalysts. Shares of Palisade Bio In…
Carlsbad, CA, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company advancing novel therapeutics for patients living with autoimmune,…
(RTTNews) - A wave of after-hours activity swept through select biotech and medical device names Thursday, with several micro- and mid-cap stocks posting sharp gains following session-end catalysts, volume spikes, or pipeline updates. Belo…
Offering was led by B Group Capital and Columbia Threadneedle Investments with significant participation from Adage Capital Partners LP, ADAR1 Capital Management, Boxer Capital Management, Coastlands Capital, Deep Track Capital, Janus Hend…
* Palisades Goldcorp (TSXV:PALI:CA [https://seekingalpha.com/symbol/PALI:CA]) appointed [https://seekingalpha.com/pr/20252157-palisades-announces-management-update] Jeff Stieber as the company's CFO, effective immediately. * The appointmen…
Carlsbad, CA, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with aut…
Carlsbad, CA, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company advancing novel therapeutics for patients living with autoimmune,…
Carlsbad, CA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company advancing novel therapeutics for patients living with autoimmune,…
PALI-2108 demonstrated favorable safety, with no serious adverse events, lab abnormalities, or EKG concerns Phase 1b data demonstrated 100% clinical response and promising signals regarding the efficacy of PALI-2108 in ulcerative colitis (…
First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies Patient dosing expected to commence in H2 2025; Topline data anticipated in Q1 2026 Continued progress toward P…
– Moderated discussion with leading expert in Fibrostenotic Crohn's Disease (FSCD) and Inflammatory Bowel Diseases (IBD), Dr. Brian Feagan – Segment provides further insight into the need for more effective treatment options for FSCD and h…
* Palisade Bio (NASDAQ:PALI [https://seekingalpha.com/symbol/PALI]) filed to register up to 8.9M shares of common stock for resale by selling stockholders. * The shares include 8.64M issuable upon exercise of a warrant from a private place…
NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change CIMG Inc. 470,278,391 0.6923 0.44 0.6225 +0.4225 LQR House Inc. 97,477,171…
PALI-2108 demonstrated to be safe and well tolerated with no serious adverse events (SAEs) Extended half-life and local bioactivation support convenient once-daily dosing in ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD)…
PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn’s disease (FSCD) and ulcerative colitis (UC), to address significant unmet medical needs Inflammatory Bowel Disease is a lar…
These stocks have an unusual volume in today's session [unusualvolume] UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT MCVT [https://www.chartmill.com/stock/quote/MCVT/profile] 13.48% MILL CITY VENTURES III LTD (NASDAQ:MCVT [https://www.chartm…
These stocks have an unusual volume in today's session [unusualvolume] UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT ORIS [https://www.chartmill.com/stock/quote/ORIS/profile] -9.49% ORIENTAL RISE HOLDINGS LTD'S (NASDAQ:ORIS [https://www.char…